Word: bristols
(lookup in dictionary)
(lookup stats)
Dates: all
Sort By: most recent first
(reverse)
...Food and Drug Administration and the Justice Department over alleged manufacturing improprieties in Puerto Rico. The company denied any wrongdoing, but the market did not care. J&J's drop contributed 55 points to the Dow's Friday freak-out, and the company joins Merck & Co. and Bristol-Myers Squibb (which face sales-accounting questions) under investors' microscope...
...MUCH HYGIENE Cleaner is not always better, according to a report published in Archives of Disease in Childhood. A study at the University of Bristol England followed 11,000 kids for more than three years. Researchers found that young children who were bathed or washed more than twice a day were more likely to have severe eczema or asthma, suggesting that too much cleanliness inhibits a child's natural immune responses to everyday bacteria. --By Lisa McLaughlin
That's not huge bucks for a company with $17 billion in revenues, as Halliburton reported in 1998. But scandals over what counts as sales took Xerox down a peg over the last year and have caught up with drug companies Merck and Bristol-Meyers Squibb. The Judicial Watch lawsuit alleges that Halliburton used the revenue-enhancement gimmick to ward off investor scrutiny as the company's financials deteriorated when the oil industry retrenched. Revenues fell anyway, to $12 billion by 2000, Cheney's last year in command...
...rise in Russia and China, both of which are predicted to become the next hot spots of the disease. Earlier this month, 15 Caribbean nations agreed to purchase desperately needed AIDS drugs from major pharmaceutical companies - at discounts of up to 90 percent. The companies, including Abbot Laboratories, Bristol-Myers Squibb and Merck decided it was more expedient to strike a deal with the Caribbean as a region, rather than wrangle with the individual countries. Local leaders called the agreement a "major victory" in the fight against AIDS...
Erbitux, though, promised to wash those troubles away. Last October Sam and Harlan sold stock for $57 million and $54 million, respectively, as part of a deal with Bristol-Myers. But Harlan followed up with a second sale worth $50 million on Dec. 6--just two days after the FDA first privately indicated to ImClone that there might be problems with the Erbitux application. His attorney told the Los Angeles Times that the timing of that sale was "coincidental...